ʻO Lilly, kahi hui ʻAmelika, a me Novo Nordisk, kahi hui Denemaka, ua hoʻolaha kūleʻa i ka ʻikepili kūʻai aku o kā lākou huahana nui ma 2020: Ua lilo ʻo Dulaglutide i lāʻau TOP1 GLP-1, me ke kūʻai aku ʻana o $ 5.07Bn i 2020, hoʻokahi makahiki- ma ka makahiki hoʻonui o 22.8%;liraglutide E hoʻomaka ana e komo i kahi manawa iho, ua hāʻule ke kūʻai aku ma 2020 mai $4.14Bn a i $3.93Bn, hoʻemi i ka makahiki o ka makahiki he 5.1%;Ua ulu wikiwiki ka semaglutide, me ke kūʻai aku i $ 3.72Bn i 2020, kahi hoʻonui makahiki o 119.9%.
Ua hoʻokumu ʻia ka dulaglutide o Lilly (inoa kalepa ʻo Trulicity®) i ka makahiki 2014 a lilo i lāʻau blockbuster me ke kūʻai aku ʻana o $5.07Bn i nā makahiki 6 wale nō, e lilo ana i poʻokela kūʻai o nā lāʻau lapaʻau GLP-1.ʻO ka huahana hoʻokahi a Novo Nordisk ua lohi iki ma hope o Lilly.ʻO kāna liraglutide (inoa kālepa ʻo Victoza® a me Saxenda®), i hoʻokuʻu ʻia i ka makahiki 2009, ʻo ia ke poʻokela kūʻai o nā lāʻau lapaʻau GLP-1, a ʻo kāna kūʻai kiʻekiʻe ma 2017 a hiki i $ 4.37Bn, ʻoiai aia ʻelua mau hōʻailona no ka maʻi diabetes type II a me ka momona. , hōʻike ka ʻikepili no 2020 ua komo ka mākeke no kēia lāʻau i kahi manawa o ka emi ʻana.ʻO ka Novo Nordisk's semaglutide (inoa kālepa ʻo Ozempic® a me Rybelsus®) ua ulu wikiwiki a ua ulu a lilo i lāʻau blockbuster ʻē aʻe me ke kūʻai ʻana o $ 3.72Bn i ʻekolu makahiki.Loaʻa i ka lāʻau lapaʻau nā ʻano ʻelua o ka injection a me ka hoʻomākaukau waha.
Mai kahi hiʻohiʻona ʻāina, ʻo ʻAmelika ka ʻāina kūʻai nui o ka liraglutide, e helu ana ma kahi o 60% i 2020, kahi hoʻemi o ka makahiki ma ka makahiki o 11.02%;ʻo ia hoʻi ka recession i ʻAmelika Hui Pū ʻIa i hoʻomaka i ka emi ʻana o ka mākeke honua no ka liraglutide.Ua ulu mālie ka ʻāina EMEA (Europe, Middle East, Africa), me kahi CAGR o 1.6% wale nō i nā makahiki ʻelima i hala;ʻO Kina ka mākeke ulu wikiwiki loa, me ke kūʻai aku ʻana o $ 182.50Mn i 2020, me ka nui o ka ulu ʻana o ka makahiki he 42.39%.No ka mea ua hiki koke mai ka semaglutide ma ka mākeke, aia nā mākeke āpau i kahi pae o ka ulu wikiwiki.ʻO ʻAmelika Hui Pū ʻIa ka mākeke nui loa, e helu ana no 80.04% o ke kūʻai aku ma 2020, kahi hoʻonui makahiki-ma-makahiki o 106.08%;He 13.64% wale nō ka māhele o EMEA akā he 249.65% ka ulu makahiki o ka makahiki.Ua hoʻokuʻu ʻia ʻo Semaglutide ma Kina i 2020 me ke kūʻai aku ʻana o $ 1.61Mn.Hōʻike ke kiʻi 3 i ke kūlana kūloko o dulaglutide.Ma ke ʻano he mākeke nui loa, ua kūʻai aku ʻo ʻAmelika Hui Pū ʻIa e like me $3.836Bn, helu ʻia no 75.69%, me ka nui o ka ulu ʻana o ka makahiki he 79.18%.
ʻO nā patent koʻikoʻi no ka liraglutide (Victoza® a me Saxenda®) ua pau i Kina a kokoke e pau i ka US, Iapana a me Kelemānia.Ua hoʻopaʻa ʻia ke kaua patent a Teva me Novo Nordisk, a e loaʻa ana ka mana maʻamau o Teva ma 2023. Ua waiho pū ʻo Mylan i kahi noi ANDA me ka FDA no ka liraglutide me kahi koi PIV.Me ka pau ʻana o nā patent koʻikoʻi a me ka hoʻoweliweli o nā mea hana lāʻau maʻamau, e komo mālie ka lāʻau lapaʻau i kahi manawa o ka emi ʻana.ʻAʻole e pau ka patent hui US o Trulicity® a hiki i 2027, aʻo nā patent hui o nā ʻāina nui ʻEulopa a me Iapana ʻaʻole e pau a hiki i 2029, a ʻoi aku ka lōʻihi o ka pale patent ma mua o ka liraglutide.ʻO nā patent nui o semaglutide (Ozempic® a me Rybelsus®) e pau i ka makahiki 2032 ma ka hope loa, a aia kahi lumi nui no ka ulu ʻana o ka mākeke, akā ʻo kona manawa pau i Kina ʻo 2026.
Ka manawa hoʻouna: Iulai-25-2022